HONG KONG, CHINA�-�EQS -�14�June 2019 - A fully
integrated biopharmaceutical company -- Uni-Bio Science Group Limited (the
"Company", together with its subsidiaries, the "Group"; Stock code: 0690.HK), and
its subsidiary, Uni-Bio Science HealthCare Ltd. are pleased to announce that a Letter
of Intent for strategic cooperation framework has been signed with Kaiping Time
City Tourism Development Co., Ltd. ("the partner"). The Letter of
Intent aims to cooperate with the partner in the construction and operation of
the chronic illness rehabilitation base and related healthcare facilities combining with the services of Chronic Disease
Management.

Within the
next 6 months, both parties will further evaluate the financial feasibility of
the project and finalize a deal structure that can better leverage the
strengths of each company and lead to a win-win partnership. The successful
signing of this cooperation will directly benefit the long-term sales of the
Group's chronic disease product portfolio, especially the soon-to-launch rhExendin-4
("Uni-E4") and rhPTH (1-34) ("Uni-PTH") to treat diabetes
and osteoporosis, respectively. Chronic diseases are long-term conditions that
usually progress slowly over time, therefore it is often best managed through a
comprehensive program that includes education on health, proactive lifestyle
changes, well-integrate primary care and aftercare, and drug treatment. By
working with our partner, we can integrate our products in a broader chronic
disease treatment solution for more effective results for our patients. This
approach also corresponds to the strong support of Guangdong Province and local
governments for the development of great health industries.

On the
signing of this Letter of Intent of the strategic cooperation, Mr. Kingsley Leung, Chairman of and Executive Director of Uni-Bio
Science Group Limited said, "With the improvement of living standards and
the arrival of "aging China", the biggest problem threatening people's health
is chronic diseases. The Outline of the
2030 Plan for Healthy China upgrades the management and rehabilitation of
chronic diseases to a new strategic level. It is not only the needs of the
country but also the demand of the people. The Group's product line and
innovative Biological drugs for the treatment of chronic diseases will be released
on the market in the near future, providing a new avenue to treat these
diseases that affect over 300 Million people in China alone. It is worth
emphasizing that Uni-PTH and Uni-E4 are relatively new products in the Chinese
market. They are cost-effective products that solve unmet needs in osteoporosis
and diabetes, respectively. However, they are fairly expensive compared to
common copy-cat chemical drugs and will require education to physicians and
patients on their clinical uniqueness. This opportunity to expand our
value-chain further downstream to the private healthcare space will allow the
Group to access our target market directly and more cost-effectively. It will
enable us to better educate our customers, as well as receive feedback for our
products much quicker. Our partner is planning to invest up to RMB Six Billion
Yuan into the overall project. When completed, the project will attract significant
patient flow!

Mr. Leung continued: "The cooperation between the two sides not only has a
very good starting point, but also has a huge potential for further
development. In particular, the Group can also provide medical training for
health care institutions, technical and operational services for pre-market phase
I or post-market phase IV clinical trials of drugs, and can quickly obtain
first-hand clinical data for faster and more successful drug development for
the Group in the future. "

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally
engaged in the research and development, manufacture and distribution of
pharmaceutical products. The research and development center is fully equipped
with a complete system for the development of genetically-engineered products
with a pilot plant test base which is in line with NMPA requirements. The Group
also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is
focused on the development of novel treatments and innovative drugs addressing
the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology
and dermatology.

Uni-Bio Science Group Limited
was listed on the Main Board of the Hong Kong Stock Exchange on November 12,
2001. Stock code: 0690.